Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists
Por:
Sanchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martinez-Janez N, Martinez-de-Duenas E, Lluch A, Illarramendi J, Gomez-Pardo P, Gregori J, Garcia-Palomo A, Garcia-Mata J, Fernandez Y, del Barco S, de Juan A, Ciruelos E, Chacon J, Calvo L, Barnadas A, Albanell J
Publicada:
1 ene 2019
Resumen:
Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic treatment of metastatic breast cancer (MBC) according to patient profiles.
Methods: A self-administered questionnaire was developed, divided into five sections comprising 34 specific questions related to sequential treatments, plus three additional general questions. Respondents were asked to justify negative answers. Participants were recruited randomly by invitation out of a total of 619 oncologists. The questionnaire was sent and collected via e-mail between October 2015 and May 2016. A total of 191 completed questionnaires were received.
Results: Overall, 70% of oncologists would keep the three patient profiles exactly as proposed (hormone receptor-positive and HER2-negative, HER2-positive, and triple negative breast cancer). Affirmative answers to questions regarding treatment sequences for these patient profiles (1-34) ranged from 77.8-99.5%, with an average of 90.9% of oncologists being in agreement with the recommended sequential treatments. The lowest degree of consensus was observed for endocrine treatments in pre-menopausal women and for chemotherapy options in hormone-resistant patients, whilst the highest degree of consensus was reached for targeted therapies in HER2-positive patients and for endocrine therapy in post-menopausal women. In their comments, participants revealed a number of economic constraints that prevented them from implementing some of the best treatment options.
Conclusions: In conclusion, despite the complexity of MBC treatment, there is general agreement on the optimal treatment sequences.
Filiaciones:
Sanchez-Rovira P:
Complejo Hosp Jaen, Avda Ejercito Espanol 10, Jaen 23007, Spain
Zamora P:
Hosp Univ La Paz, Madrid, Spain
Salvador-Bofill J:
Hosp Univ Nuestra Senora Valme, Seville, Spain
Morales S:
Hosp Universitari Arnau de Vilanova, Lleida, Spain
Martinez-Janez N:
Hosp Univ Ramon y Cajal, Madrid, Spain
Martinez-de-Duenas E:
Consorcio Hosp & Prov Castellon, Castellon de La Plana, Spain
Lluch A:
Hosp Clin Univ Valencia, Valencia, Spain
Illarramendi J:
Complejo Hosp Navarra, Pamplona, Spain
Gomez-Pardo P:
Hosp Univ Vall dHebron, Barcelona, Spain
Gregori J:
Fdn Inst Valenciano Oncol, Valencia, Spain
Garcia-Palomo A:
Complejo Asistencial Leon, Leon, Spain
Garcia-Mata J:
Hosp Santa Maria Nai Ourense, Orense, Spain
Fernandez Y:
Hosp Univ Cent Asturias, Oviedo, Spain
del Barco S:
Inst CataladOncol, Girona, Spain
de Juan A:
Hosp Univ Marques de Valdecilla, Santander, Spain
Ciruelos E:
Hosp Univ 12 Octubre, Madrid, Spain
Chacon J:
Hosp Virgen Salud, Toledo, Spain
Calvo L:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Barnadas A:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Albanell J:
Hosp del Mar, Barcelona, Spain
|